RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:WowI think there is a good reason he set the 29th. If Aristotle is being released anytime after today than those shareholders that are the long term holders and not those coming in to flip on the news or to ride the wave.
That would suggest to me there will be some important votes coming. Too early for buyout would love to see the partnerships and Nasdaq sooner than later.
InvrsContrarian wrote: The numbers haven't even been testing yet. 1000's of tests per day and revenue from their main product to be considered a buyout. Google liquid biopsy companies and stage zero is a dark horse. I'll give that, a sneak attack, you can't defend what you don't see. Maybe two years of revenues would be the time to consider a buyout. Not likely any time soon. But hey liquid biopsy companies are earning 35 time p/e right now. So that is something to shoot for the first year out. Rookie contract time.
Nailbiter1 wrote: ompong12 wrote: StockscoutX wrote: I get the feeling that an early meeting could indicate a very important decision the shareholders must take.
i Vote for the BUY OUT.....take over is the KEY
Way ahead of yourself junior. Wanting a quick exit to satisfy a perpetual sweet tooth?
Premature e-sellulation happens to many.
If you believe in this tech's full potential, you'd wait for max results on multiple disease diagnostics.
I vote NAY for a premature buyout.
Roll out and expand.